Arrowhead Pharmaceuticals, Inc.

Arrowhead Pharmaceuticals Beats on EPS, Stock Up 0.0%

Arrowhead Pharmaceuticals reported a narrower-than-expected loss per share, which was a positive surprise for investors. However, the stock reaction was flat, indicating that investors may be waiting for more substantial news or guidance before making further decisions. The lack of revenue figures and management commentary leaves some uncertainty about the company's current performance and future outlook.